Wire · opportunities
Genprex collaborates with Roche Diagnostics for biomarker assay validation studies
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 August 2026 · Fusion42 review
Genprex has partnered with Roche Diagnostics to validate the use of TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials, leveraging Roche's FDA Breakthrough Device Designated AI-driven diagnostic assay to improve precision in oncology treatments.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 3 Aug 2026 and 4 Aug 2026.
◆ ◆ The Wire takeaway
Roche's FDA designation for their AI-driven TROP2 assay opens a faster path for you to recruit targeted NSCLC patients with greater precision. This partnership lets you shortcut patient selection with a validated companion diagnostic, accelerating your trial timelines and competitive edge.
◆ Coverage
2 sources · first reported 3 Aug 2026 · latest 4 Aug 2026
◆ Related on Wire
◆ Topics